CareDx vs Castle Biosciences
CDNA and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDNA and CSTL compare
CareDx is the larger company, worth 4.1 times as much as Castle Biosciences ($4.3B against $1.0B).
CareDx grew revenue faster over the last twelve months (38.9% versus 9.8% for Castle Biosciences).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with −6.1% at Castle Biosciences.
CareDx scores higher on the StockData Score (12 against 11 for Castle Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDNA | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $1.0B |
| Share price | $81.17 | $33.99 |
| Change, 1 year | 386% | −2.2% |
| Change, 5 years | 88.7% | −28.4% |
| Beta (5Y) | 1.52 | 1.38 |
| Employees | 765 | 883 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 34.0× | – |
| P/S | 8.6× | 2.8× (better) |
| P/B | 9.1× | 2.2× (better) |
| EV/EBITDA | 29.9× | – |
| P/FCF | – | 262× |
| FCF yield | – | 0.38% |
| Fair value | $66.02 | $36.69 |
| Margin of safety | −22.9% | 7.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 38.9% (better) | 9.8% |
| Revenue growth, 5Y average | 14.6% | 40.6% (better) |
| Net income growth (TTM) | 82.6% | – |
| Profitability | ||
| Gross margin | – | 77.1% |
| Operating margin | 23.4% (better) | −7.4% |
| Net margin | 25.9% (better) | −6.1% |
| FCF margin | – | 1.1% |
| Return on equity | 33.0% (better) | −4.9% |
| Return on invested capital | 69.8% (better) | −11.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.02 (better) |
| Interest coverage | – | −51.2× |
| Current ratio | 2.31 | 5.28 (better) |
| Altman Z-score | 15.36 (better) | 6.67 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 89.5% |
| Held by insiders | 4.8% | 1.9% |
| Insider net buying, 12 months | −$18.1M (better) | −$18.1M |
| Short interest, % of float | 14.4% | 7.0% |
Go deeper
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.